The merchandise is described as prescription-only Chantix (Varenicline) tablets for the treatment of nicotine dependency associated with smoking in adults. The Chantix tablets contain the active ingredient Varenicline, a nicotinic receptor partial agonist, and are indicated for use as an aid to smoking-cessation treatment. They are supplied for oral administration in two strengths. Unlike other anti-smoking products, such as nicotine replacement therapy (“NRT”) chewing gum tablets and transdermal administration patches that contain nicotine, the Chantix tablets do not contain nicotine, but instead employ the active ingredient Varenicline, which binds to a patient’s nicotine receptors, thereby providing the patient with a replacement for nicotine otherwise obtained through smoking. The Chantix tablets are approved for use by the U.S. Food and Drug Administration (FDA) and are administered by prescription only, under the supervision of a physician, during a multi-week, smoking-cessation therapy program.
[1] Please importantly note that only the relevant portion of the related is displayed above. You may refer to the said customs ruling for the entire ruling explanation.
[1]. https://rulings.cbp.gov/ruling/H239874